Close Menu

stomach cancer

After the VOYAGER study failed to show a PFS advantage for its drug, the company said it will focus on commercializing the drug in the molecularly defined indication.

The company filed for approval of the therapy in patients with advanced, PDGFRA exon 18-mutated gastrointestinal stromal tumors.